BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · Real-Time Price · USD

7.61

-0.07 (-0.91%)

At close: Nov 13, 2026, 4:00 PM EST

7.61

0.00 (-0.01%)

After-hours: Nov 13, 2026, 7:55 PM EST

BioCryst Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	961.51	874.84	450.71	331.41	270.83	157.17
Revenue Growth	60.30%	94.10%	36.00%	22.37%	72.31%	782.38%
Gross Profit	751.18	691.68	265.01	114.94	10.94	-58.9
Operating Income	468.76	347.3	-1.28	-98.78	-148.44	-177.72
Net Income	-359.66	263.86	-88.88	-226.54	-247.12	-184.06
Earnings Per Share	-1.49	1.21	-0.43	-1.18	-1.33	-1.03
EPS Growth	-	-	-	-	-	-

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
United States	548.78	385.96	288.36
Outside United States	53.06	51.7	37.63
Unallocated	273	13.05	5.42
Total	874.84	450.71	331.41

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	375	274.75	320.85	388.99	424.31	507.6
Total Debt	828.2	477.33	841.42	848.71	741.45	593.24
Net Cash (Debt)	-453.2	-202.58	-520.57	-459.73	-317.14	-85.64
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-1.88	-0.93	-2.52	-2.39	-1.71	-0.48

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	367.49	347.37	-52.02	-95.14	-161.85	-142.16
Capital Expenditures	-1.65	-2.47	-1.12	-2.17	-1.35	-2.39
Free Cash Flow	365.85	344.9	-53.14	-97.31	-163.2	-144.54
Free Cash Flow Growth	664.49%	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	78.13%	79.06%	58.80%	34.68%	4.04%	-37.48%
Operating Margin	48.75%	39.70%	-0.28%	-29.81%	-54.81%	-113.07%
Pretax Margin	-36.89%	30.56%	-19.29%	-68.26%	-90.24%	-115.68%
Profit Margin	-37.41%	30.16%	-19.72%	-68.36%	-91.25%	-117.11%
FCF Margin	38.05%	39.42%	-11.79%	-29.36%	-60.26%	-91.97%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	6.22	-	-	-	-
Forward PE	11.75	33.02	-	-	-	-
P/FCF Ratio	5.35	4.76	-	-	-	-
PS Ratio	2.04	1.88	3.46	3.70	7.90	15.86